Avidity Biosciences Inc. — Sponsor Intelligence | 5 EU Trials

Filter these 5 trials by condition, phase, country and more.

5 Registered trials

2 Recruiting

2 Completed trials

9 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase I (FiH)

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

5 total

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In… Pending

2025-523087-20-00 Phase III 7 countries DELPACIBART ZOTADIRSEN
A Global Phase 3 Open-Label Extension Study to Assess AOC 1001 in Patients with DM1 Recruiting

2025-520766-22-00 Phase III 6 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SI…
A Phase 3 Study to Evaluate AOC 1020 in Participants with FSHD Recruiting

2025-521012-18-00 Phase III 6 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SI…
A Phase 3 Global Study to Evaluate AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 Ended

2024-511378-60-00 Phase III 7 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SI…
Phase 1/2 Study of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Ended

2022-502096-32-00 Phase I (FiH) 2 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SI…

Showing 1–5 of 5 trials